MABE1125

Anti-BORIS/CTCFL Antibody, clone 4A7

clone 4A7, from human(Recombinant)

• Synonym(s): Transcriptional repressor CTCF, BORIS-like protein, Brother of the regulator of imprinted sites, Cancer/testis antigen 27, CTCF-like protein, CTCF paralog, HMG-1L1, Putative high mobility group protein 1-like 1, Putative high mobility group protein B1-li
• UNSPSC Code: 12352203
• eCl@ss: 32160702
• NACRES: NA.41

Properties

• biological source: human (Recombinant)
• Quality Level: 100
• antibody form: purified immunoglobulin
• antibody product type: primary antibodies
• clone: 4A7, monoclonal
• species reactivity: mouse, human
• technique(s): ChIP: suitable; immunocytochemistry: suitable; immunohistochemistry: suitable; western blot: suitable
• isotype: IgMκ
• NCBI accession no.: NP_001255969.1
• UniProt accession no.: Q8NI51
• shipped in: wet ice
• target post-translational modification: unmodified
• Gene Information: human ... CTCFL(140690)

Description

General description

Transcriptional repressor CTCFL (UniProt Q8NI51; also known as BORIS-like protein, Brother of the regulator of imprinted sites, Cancer/testis antigen 27, CTCF-like protein, CTCF paralog, HMG-1L1, Putative high mobility group protein 1-like 1, Putative high mobility group protein B1-like 1, Zinc finger protein CTCF-T) is encoded by the CTCFL (also known as BORIS, CT27, CTCF-T, dJ579F20.2, HMGB1L1) gene (Gene ID 140690) in human. BORIS is a member of the cancer-testis antigen (CT) family of proteins. BORIS is normally present at high levels in the testis, however it is also aberrantly expressed in various tumors and cancer cell lines. The central DNA-binding region of BORIS is composed of 11 zinc-finger domains similar to CTCF, while the flanking N- and C-terminal regions are distinct between these two paralogs. The appearance of BORIS during germ-line development suggests a role in epigenetic reprogramming in germ cells. BORIS protein is detected in all prostate cell lines and prostate tumors, but it is absent in benign prostatic hyperplasia tissues. Furthermore, increased BORIS protein levels correlate with higher Gleason scores, T-stage and androgen receptor (AR) protein levels in prostate tumors. BORIS is predominantly cytoplasmic in the benign prostatic hyperplasia (BPH) epithelial cell line BPH-1, while BORIS is found to be localized both in the cytoplasm and nucleus among tumorigenic BPH-1 derivatives and established prostate cancer cell lines.

Specificity

Expected to react with spliced isoforms 1, 2, 3, 4, 7, 8, 9, but not isoforms 6 and 11. Reactivity to isoforms 5 and 10 has not been determined.

Immunogen

Epitope: Region N-terminal to zinc fingers

His-tagged recombinant human BORIS/CTCFL N-terminal fragment.

Application

Anti-BORIS/CTCFL Antibody, clone 4A7 is an antibody against BORIS/CTCFL for use in Western Blotting, Chromatin Immunoprecipitation (ChIP), Immunocytochemistry, Immunohistochemistry.

Research Category
Epigenetics & Nuclear Function

Research Sub Category
Chromatin Biology

Western Blotting Analysis: 0.5 µg/mL from a representative lot detected BORIS/CTCFL in 10 µg of NIH/3T3 and LNCaP cell lysates.
Western Blotting Analysis: A representative lot detected bacterially expressed Boris N-terminal recombinant fragment, as well as endogenous Boris in mouse embryonic fibroblasts, NIH/3T3, HEK293T, and human prostate cancer cell lines, including PC3, LNCaP, and DU145 (Cheema, Z., et al. (2014). Prostate. 74(2):164-176).
Immunocytochemistry Analysis: A representative lot detected a much greater Boris immunoreactivity among human prostate cancer cell lines than the benign prostatic hyperplasia (BPH) epithelial cell line BPH-1 by both flourescent and non-fluorescent immunocytochemistry (Cheema, Z., et al. (2014). Prostate. 74(2):164-176).
Chromatin Immunoprecipitation Analysis: A representative lot detected comparable Boris occupany as CTCF at the known CTCF-targeting site (CTS) around PIM-1, while a much weaker association of Boris with another CTS, the Igf2/H19 imprinting control region (H19 ICR) was observed using chromatin preparations from human LNCaP prostate cancer cells (Courtesy of Dr. E. Klenova, University of Essex, UK).
Immunohistochemistry Analysis: A representative lot detected Boris immunoreactivity among frozen sections of prostate tumours, but not benign prostatic hyperplasia (BPH) tissues (Cheema, Z., et al. (2014). Prostate. 74(2):164-176).

Quality

Evaluated by Western Blotting in MCF7 cell lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected BORIS/CTCFL in 10 µg of MCF7 cell lysate.

Target description

~83/70 kDa observed. 75.7 kDa (isoform 1), 66.0 kDa (isoform 2), 75.8 kDa (isoform 3), 54.2 kDa (isoform 4), 48.1 kDa (isoform 5), 46.5 kDa (isoform 6), 80.0 kDa (isoform 7), 69.9 kDa (isoform 8), 48.9 kDa (isoform 9), 52.7 kDa (isoform 10), 35.4 kDa (isoform 11) calculated.

Physical form

Format: Purified

Purified mouse monoclonal IgMκ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Storage and Stability

Stable for 1 year at 2-8°C from date of receipt.

Other Notes

Concentration: Please refer to lot specific datasheet.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Storage Class Code: 12 - Non Combustible Liquids
• WGK: WGK 1
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable